Considerations for Risk Stratification, Evaluation of Currently Available Therapies, and Examining Bispecific Antibodies in Development for Relapsed/Refractory Setting of Multiple Myeloma
This enduring educational activity will focus primarily on risk stratification and best practices to more accurately inform treatment sequencing in patients with relapsed/refractory multiple myeloma; explore mechanisms of action of innovative therapies for multiple myeloma; and evaluate new and emerging bispecific anti-BCMA and anti-FcRH5 clinical trial data in the setting of relapsed/refractory multiple myeloma.
RELEASED DATE: April 26, 2024
EXPIRATION DATE: April 26, 2025
Visualizing the Mechanistic Features of BCMA-Directed Bispecific Antibodies: Updates in Relapsed/Refractory Multiple Myeloma
This Virtual Preceptorship invites learners to explore the mechanisms of bispecific antibodies in the management of relapsed/refractory multiple myeloma. Novel bispecific antibodies simultaneously target CD3 on immune T cells and a target on malignant B cells, such as BCMA. By guiding T cells to malignant myeloma cells, bispecific antibodies enable the precise immune attack of malignant cells. In the process of immune attack, bispecific antibodies may trigger adverse events that require careful monitoring and multidisciplinary management. In this virtual reality program, clinicians will gain perspectives on both mechanisms and safe use of bispecific antibodies in patients with relapsed/refractory multiple myeloma.
RELEASED DATE: January 24, 2024
EXPIRATION DATE: January 24, 2025
